Results 21 to 30 of about 109,968 (264)

Research Progress of Multi-target CAR-T Cell Therapy for Cancer

Zhongliu Fangzhi Yanjiu, 2022
Chimeric antigen receptor T cell (CAR-T) is a kind of adoptive cell immunotherapy, in which T cells are genetically modified to exert targeted killing effect on tumors.
JIANG Yao, WEN Weihong, YANG Fa, NIE Disen, ZHANG Wuhe, QIN Weijun   +5 more
doaj   +1 more source

Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review

Advances in Cancer Biology - Metastasis, 2022
Cancer is the leading cause of death globally after cardiovascular diseases. Conventional therapeutic strategies have had minimal success rate. Recently, immunotherapy, particularly chimeric antigen receptor T cells (CAR T cells), has emerged as the most
Ubaid Ahmad, Zafran Khan, Daniya Ualiyeva, Obed Boadi Amissah, Zohaib Noor, Asaf Khan, Nasib Zaman, Marwa Khan, Ayub Khan, Babar Ali   +9 more
doaj   +1 more source

Mesothelin-targeting chimeric antigen receptor–modified T cells by transposon system suppress the growth of bile duct carcinoma

Tumor Biology, 2017
Chimeric antigen receptor modified T cell–based immunotherapy is revolutionizing the field of cancer treatment. However, its potential in treating bile duct carcinoma has not been fully explored.
Jie-Ying Xu, Zhen-Long Ye, Du-Qing Jiang, Jiang-Chuan He, Yong-Mei Ding, Lin-Fang Li, Sai-Qun Lv, Ying Wang, Hua-Jun Jin, Qi-Jun Qian   +9 more
doaj   +1 more source

Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer

BMC Cancer, 2018
Background Salivary gland cancers are not sensitive to conventional radiotherapy or chemotherapy regimens. Therefore, the development of a new treatment strategy is of critical importance for improving the prognosis.
Yuji Makita, Naoki Kunii, Daiju Sakurai, Fumie Ihara, Shinichiro Motohashi, Akane Suzuki, Toshinori Nakayama, Yoshitaka Okamoto   +7 more
doaj   +1 more source

Therapeutic applications of engineered chimeric antigen receptors-T cell for cancer therapy

Beni-Suef University Journal of Basic and Applied Sciences, 2022
Background Findings of new targeted treatments with adequate safety evaluations are essential for better cancer cures and mortality rates. Immunotherapy holds promise for patients with relapsed disease, with the ability to elicit long-term remissions ...
Amina Hussain
doaj   +1 more source

Drug functional remapping: a new promise for tumor immunotherapy

Frontiers in Oncology
The research and development of new anti-cancer drugs face challenges such as high costs, lengthy development cycles, and limited data on side effects.
Jiayi Dong, Jiayi Dong, Jiayi Dong, Ting Su, Ting Su, Ting Su, Ting Su, Jiexiong Wu, Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Minghan Song, Minghan Song, Minghan Song, Canfeng He, Canfeng He, Canfeng He, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Yubin Yang, Yubin Yang, Size Chen, Size Chen, Size Chen, Size Chen   +27 more
doaj   +1 more source

Chimeric antigen receptor natural killer cell therapy for solid tumors: mechanisms, clinical progress, and strategies to overcome the tumor microenvironment

Experimental Biology and Medicine
Natural killer (NK) cells represent a fundamental component of the innate immune system, endowed with the ability to identify and eradicate virus-infected and malignant cells.
Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Yu Xiang, Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiayi Dong, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Size Chen, Size Chen, Size Chen, Size Chen, Size Chen   +18 more
doaj   +1 more source

T cell receptor-engineered T cells for leukemia immunotherapy

Cancer Cell International, 2019
At present, refractory and relapse are major issues for leukemia therapy and a major cause of allogeneic hematopoietic stem cell transplant failure. Over the last decade, many studies have demonstrated that adoptive cancer antigen-specific T cell therapy
Yikai Zhang, Yangqiu Li
doaj   +1 more source

In-depth analysis of the safety of CAR-T cell therapy for solid tumors

Frontiers in Immunology
In recent years, the rapid progress in oncology, immunology, and molecular biology has dramatically advanced cancer immunotherapy, particularly CAR-T cell therapy.
Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiayi Dong, Jiexiong Wu, Ye Jin, Ye Jin, Ye Jin, Ye Jin, Ye Jin, Zhu Zheng, Zhu Zheng, Zhu Zheng, Zhu Zheng, Zhu Zheng, Ting Su, Ting Su, Ting Su, Ting Su, Ting Su, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Lijuan Shao, Jiaxin Bei, Jiaxin Bei, Jiaxin Bei, Jiaxin Bei, Size Chen, Size Chen, Size Chen, Size Chen, Size Chen   +33 more
doaj   +1 more source

Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma

Haematologica, 2016
Adoptive transfer of chimeric antigen receptor-transduced T cells is a promising strategy for cancer immunotherapy. The CD38 molecule, with its high expression on multiple myeloma cells, appears a suitable target for antibody therapy.
Esther Drent, Richard W.J. Groen, Willy A. Noort, Maria Themeli, Jeroen J. Lammerts van Bueren, Paul W.H.I. Parren, Jürgen Kuball, Zsolt Sebestyen, Huipin Yuan, Joost de Bruijn, Niels W.C.J. van de Donk, Anton C.M. Martens, Henk M. Lokhorst, Tuna Mutis   +13 more
doaj   +1 more source